モメタゾンフランカルボン酸エステル

Corticosteroid for topical cutaneous, intranasal or inhaled application. Indicated for the treatment of asthma, allergic rhinitis and atopic dermatitis, psoriasis and contact eczema. Authorized use in pediatrics from 3 years of age (rhinitis) and 12 years of age (asthma). 

At the date of last update, we did not find published data on its excretion in breast milk.

Mometasone furoate is very poorly absorbed after inhalation, intranasal use and topical application (< 1%). 

Its pharmacokinetic data (large volume of distribution, moderately high molecular weight, high percentage of protein binding, high pKa and very low systemic absorption) make passage into breast milk of significant amounts unlikely.

In addition, its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk, 

Several medical societies and expert consensuses consider safe the use of this medication during lactation^{(Middleton 2020, National Asthma EPP 2004)}.

TOPICAL USE: If required to treat eczema or nipple dermatosis, choose the least potent corticosteroid, apply it just after the feeding so that it has been reabsorbed before the next feeding. If necessary, remove any residue with gauze ^{(Deleuran 2024, Vestergaard 2019)}; do not use for more than one week in a row.

Mineralcorticoid intoxication has occurred in an infant by continuous application of a corticosteroid to the nipple.^{(De Stefano 1983).}

Avoid application of creams, gels and other locally applied products containing kerosene (mineral oil) on the nipple so that the infant does not absorb it ^{(Concin 2008, Noti 2003)}.